Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

XOFLUZA

BALOXAVIR MARBOXIL

Standard Dose
40MG/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview XOFLUZA is listed in Drugs@FDA under application 214410 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BALOXAVIR MARBOXIL Form and strength FOR SUSPENSION;ORAL - 40MG/PACKET Sponsor GENENTECH INC Submission history Latest submission status date: 2025-05-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview XOFLUZA is listed in Drugs@FDA under application 214410 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BALOXAVIR MARBOXIL Form and strength FOR SUSPENSION;ORAL - 40MG/PACKET Sponsor GENENTECH INC Submission history Latest submission status date: 2025-05-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.